255 related articles for article (PubMed ID: 30611859)
1. The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure.
Doh CY; Li J; Mamidi R; Stelzer JE
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):661-677. PubMed ID: 30611859
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility.
Mamidi R; Li J; Doh CY; Verma S; Stelzer JE
J Am Heart Assoc; 2018 Sep; 7(17):e009627. PubMed ID: 30371160
[TBL] [Abstract][Full Text] [Related]
3. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
[TBL] [Abstract][Full Text] [Related]
4. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
[TBL] [Abstract][Full Text] [Related]
5. In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice.
Merkulov S; Chen X; Chandler MP; Stelzer JE
Circ Heart Fail; 2012 Sep; 5(5):635-44. PubMed ID: 22855556
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
7. Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfunction.
Desjardins CL; Chen Y; Coulton AT; Hoit BD; Yu X; Stelzer JE
Circ Cardiovasc Imaging; 2012 Jan; 5(1):127-36. PubMed ID: 22157650
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel interactions between domains of Myosin binding protein-C that are modulated by hypertrophic cardiomyopathy missense mutations.
Moolman-Smook J; Flashman E; de Lange W; Li Z; Corfield V; Redwood C; Watkins H
Circ Res; 2002 Oct; 91(8):704-11. PubMed ID: 12386147
[TBL] [Abstract][Full Text] [Related]
9. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.
Mamidi R; Gresham KS; Li A; dos Remedios CG; Stelzer JE
J Mol Cell Cardiol; 2015 Aug; 85():262-72. PubMed ID: 26100051
[TBL] [Abstract][Full Text] [Related]
10. Hypertrophic cardiomyopathy mutations in
Toepfer CN; Wakimoto H; Garfinkel AC; McDonough B; Liao D; Jiang J; Tai AC; Gorham JM; Lunde IG; Lun M; Lynch TL; McNamara JW; Sadayappan S; Redwood CS; Watkins HC; Seidman JG; Seidman CE
Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674652
[TBL] [Abstract][Full Text] [Related]
11. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
[TBL] [Abstract][Full Text] [Related]
12. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
13. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
14. The contribution of N-terminal truncated cMyBPC to in vivo cardiac function.
Dominic KL; Choi J; Holmes JB; Singh M; Majcher MJ; Stelzer JE
J Gen Physiol; 2023 Jun; 155(6):. PubMed ID: 37067542
[TBL] [Abstract][Full Text] [Related]
15. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice.
Li J; Mamidi R; Doh CY; Holmes JB; Bharambe N; Ramachandran R; Stelzer JE
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32750038
[TBL] [Abstract][Full Text] [Related]
16. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction.
Bahrudin U; Morikawa K; Takeuchi A; Kurata Y; Miake J; Mizuta E; Adachi K; Higaki K; Yamamoto Y; Shirayoshi Y; Yoshida A; Kato M; Yamamoto K; Nanba E; Morisaki H; Morisaki T; Matsuoka S; Ninomiya H; Hisatome I
J Mol Biol; 2011 Nov; 413(4):857-78. PubMed ID: 21939669
[TBL] [Abstract][Full Text] [Related]
17. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
18. The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position.
Mun JY; Kensler RW; Harris SP; Craig R
J Mol Cell Cardiol; 2016 Feb; 91():141-7. PubMed ID: 26718724
[TBL] [Abstract][Full Text] [Related]
19. Normal cardiac contraction in mice lacking the proline-alanine rich region and C1 domain of cardiac myosin binding protein C.
van Dijk SJ; Witt CC; Harris SP
J Mol Cell Cardiol; 2015 Nov; 88():124-32. PubMed ID: 26455481
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
